Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy

Cancer Investigation

Volumn 25, Issue 5, 2007, Pages 315-321

  Turen, Selahattin ^a   Ozyar, Enis ^a   Altundag, Kadri ^a   Gullu, Ibrahim ^a   Atahan, Ibtisam L ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; LDH; Nasopharyngeal carcinoma; Prognostic factors; Radiotherapy

Indexed keywords

CISPLATIN; CORTICOSTEROID; DIURETIC AGENT; FLUOROURACIL; LACTATE DEHYDROGENASE; SEROTONIN ANTAGONIST;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CRANIAL NEUROPATHY; DISEASE FREE SURVIVAL; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NEPHROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT PLANNING; UNIVARIATE ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 34547504562     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701209103     Document Type: Article

References (38)

1. Selek, U.; Ozyar, E.; Ozyigit, G.; Varan, A.; Buyukpamukcu, M.; Atahan, I.L. Treatment results of 59 young patients with nasopharyngeal carcinoma. Int. J. Pediatr. Otorhinolaryngol. 2005, 69, 201-207.
2. Altun, M.; Fandi, A.; Dupuis, O.; Cvitkovic, E.; Krajina, Z.; Eschwege, F. Undifferaniated nasofayngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int. J. Rad. Oncol. Biol. Pys. 1995, 32, 859-877.
3. Ho, J.H. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1978, 4, 183-205.
4. Lo, Y.M.; Chan, L.Y.; Lo, K.W.; Leung, S.F.; Zhang, J.; et al. Quantitative analysis of cell free Epstein-Barr virus DNA in plasma patients with nasopharyngeal carcinoma. Cancer Res. 1999, 59, 1188-1191.
5. Shanmugaratnam, K. Histological typing of tumors of the upper respiratory tract and ear. WHO international histological classification of tumors. 2nd ed, Berlin: Springer Verlag, 1991.
6. Baker, S.R.; Wolfe, R.A. Prognostic factors of nasopharyngeal malignancy. Cancer 1982, 49, 163-169.
7. Hsu, M.M.; Tu, S.M. Nasopharyngeal carcinoma in Taiwan. Cancer 1983, 52, 362-368.
8. Liu, T.F. Trends in the clinical management of nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1992, 23, 469-471.
9. Xiau, G.L.; Cai, W.M.; Hu, Y.H. Evaluation and revision comment of the TNM staging classification on nasopharyngeal carcinoma (NPC) proposed by UICC. Chin. J. Radiat. Oncol. 1994, 3, 6-9.
10. Liao, Y.P.; Xiao, F.; Xi, X.P. Clinical staging analysis of 2000 cases. Chin. J. Radiat. Oncol. 1993, 2, 190-191.
11. Geara, F.B.; Sanguineti, G.; Tucker, S.L.; Garden, A.S.; Ang, K.K.; Morrison, W.H.; Peters, L.J. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother. Oncol. 1997, 43, 53-61.
12. Teo, P.; Yu, P.; Lee, W.Y.; Leung, S.F.; Kwan, W.H.; et al. Significant prognostificators after primary radiotherapy in 903 non-disseminated nasopharyngeal carcinoma evaluated by computer tomography. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36, 291-304.
13. Chua, D.T.; Sham, J.S.; Kwong, D.L.; Choy, D.T.; Au, G.K.; Wu, P.M. Prognostic value of paranasopharyngeal extension of nasopharyngeal carcinoma. Cancer 1996, 76, 202-210.
14. Baker, S.R. Nasopharyngeal carcinoma: clinical course and results of therapy. Head Neck Surg. 1980, 3, 8-12.
15. Neel, III. H.B. Nasopharyngeal carcinoma. Clinical presentation, diagnosis, treatment, and prognosis. Otolaryngol. Clin. North. Am. 1985, 18, 479-485.
16. Cheng, S.H.; Jian, J.J.; Tsai, S.Y.; Chan, K.Y.; Yen, L.K.; et al. Prognostic features and treatment outcome in lokoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1998, 41, 755-762.
17. Cheng, S.H.; Yen, K.L.; Jian, J.J.; Tsai, S.Y.; Chu, N.M.; et al. Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma folloing concomitant radiotherapy and chemotherapy: impact on future clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50, 717-726.
18. Liaw, C.C.; Wang, C.H.; Huang, J.S.; Kiu, M.C.; Chen, J.S.; Chang, H.K. Serum lactate dehydrogenase level in nasopharyngeal carcinoma. Acta Oncol. 1997; 36, 159-164.
19. Sze, W.M.; Lee, A.W.; Yau, T.K.; Yeung, R.M.; Lau, K.Y.; et al. Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 21-27.
20. Fleming, I. D.; Cooper, J. S.; Henson, D. E.; Hutter, R. V. P.; Kennedy, B. J.; et al. AJCC Cancer Staging Manual. 5th ed, Lippincott-Raven, Philadelphia, 1997, 31-39.
21. Ozyar, E.; Yildiz, F.; Akyol, F.H.; Atahan, I.L. Comparison of AJCC 1988 and 1997 classifications for nasopharyngeal carcinoma. American Joint Committee on Cancer. Int. J. Radiat. Oncol. Biol. Phys. 1999, 44, 1079-1087.
22. Ozyar, E.; Yildiz, F.; Akyol, F.H.; Atahan, I.L. Adjuvant high-dose-rate brachytherapy after external beam radiotherapy in nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 101-108.
23. Kaplan, E.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53, 457-481.
24. Cox, D.R. Regression models and life tables. J. R. Stat. Soc. B 1972, 4, 187-220.
25. International Nasopharynx Cancer Study Group (INCSG). Preliminary results of a randomized trial comparing neoadjuvant chemotherapy plus radiotherapy versus radiotherapy alone in stage IV (N2, M0) undifferantiated nasopharyngeal carcinoma: a positive effect on progression-free survival. VUMCA I trial. Int. J. Radiat. Oncol. Biol. Phys. 1996, 35, 463-469.
26. Chua, D.T.; Sham, J.S.; Choy, D.; Lorvidhaya, V.; Sumitsawan, Y.; et al. Preliminary report of the Asian Oceanian Clinical Oncology association randomized trial comparing cisplatin and epirubisin followed by radiotherapy versus radiotherapy alone in the treatment of the patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 1998, 83, 2270-2283.
27. Ma, J.; Mai, H.Q.; Hong, M.H.; Min, H.Q.; Mao, Z.D.; et al. Results of a prospective randomized trial comparing chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J. Clin. Oncol. 2001, 19, 1350-1357.
28. Rossi, A.; Molinari, R.; Boracchi, P.; Del Vecchio, M.; Marubini, E.; et al. Adjuvant chemotherapy with vincristine, cyclophosphamide and doxorubicine after radiotherapy in local-regional nasopharyngeal cancer: results of a 4 year multicenter randomized study. J. Clin. Oncol. 1988, 8, 1401-1410.
29. Chi, K.H.; Chang, Y.C.; Guo, W.Y.; et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002, 52, 1238-1244.
30. Chi, K.H.; Chang, Y.C.; Guo, W.Y.; Leung, M.J.; Shiau, C.Y.; et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1995, 33, 569-577.
31. Al-Sarraf, M.; LeBlanc, M.; Giri, P.G.; Fu, K.K.; Cooper, J.; et al. Chemoradiotherapy versus raditherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J. Clin. Oncol. 1998, 16, 1310-1317.
32. Lin, J.C.; Jan, J.S.; Hsu, C.Y.; Liang, W.M.; Jiang, R.S.; Wang, W.Y. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J. Clin. Oncol. 2003, 21, 631-637.
33. Ozyar, E.; Ayhan, A.; Korcum, A.F.; Atahan, I.L.. Prognostic role of Ebstein-Barr virus latent membrane protein-1 and interleukin-10 expression in patients with nasopharyngeal carcinoma. Cancer Invest. 2004, 22, 483-491.
34. Swan, F. Jr.; Velasquez, W.S.; Tucker, S.; Redman, J.R.; Rodriguez, M.A.; et al. A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate dehydrogenase levels. J. Clin. Oncol. 1989, 7, 1518-1527.
35. Jorgensen, L.G.; Osterlind, K.; Genolla, J.; Gomm, S.A.; Hernandez, J.R.; et al. Serum neuron-specific enolase and the prognosis in small-cell lung cancer: A combinedmultivariable analysis on data from nine centres. Br. J. Cancer 1996, 74, 463-467.
36. Steyerberg, E.W.; Keizer, H.J.; Fossa, S.D.; Sleijfer, D.T.; Bajorin, D.F.; Donohue, J.P.; Habbema, J.D. Resection of residual retroperitoneal masses in testicular cancer: Evaluation and improvement of selection criteria. The ReHiT study group. Reanalysis of histology in testicular cancer. Br. J. Cancer 1996, 74, 1492-1498.
37. Chatani, M.; Matayoshi, Y.; Masaki, N. Radiation therapy of nasopharyngeal carcinoma: Treatment results and prognostic factors. Nippon Igaku Hoshasen Gakkai Zasshi 1993, 53, 945-952.
38. Hong, R.L.; Ting, L.L.; Ko, J.Y.; Hsu, M.M.; Sheen, T.S.; et al. Induction chemotherapy with mitomycin, epirubisin, cisplatin, fluorouracil and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J. Clin. Oncol. 2001, 19, 4305-4313.